May 29, 2020 10:12 AM EDTUpdated 10:36 AM
News Briefing

Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

ENDPOINTS

→ Months af­ter a de­press­ing end to Min­er­va Neu­ro­sciences‘ quest to de­vel­op a de­pres­sion drug, the Waltham, Mass­a­chu­setts-based drug de­vel­op­er un­veiled more bad news …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times